Antioxidant-1 may promote HCC carcinogenesis through the activation of the c-Myb/PI3K/AKT pathway and the inhibition of copper accumulation and oxidative stress. Despite advancements in diagnostic and ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancerPIKTOR is an ...